An Act to amend the Code of Virginia by adding in Title 59.1 a chapter numbered 22.25, consisting of a section numbered 59.1-284.46, relating to Active Pharmaceutical Ingredient Manufacturing Grant Fund.
HB800 creates the Active Pharmaceutical Ingredient Manufacturing Grant Fund within the Virginia Code to support a specific pharmaceutical manufacturing project in Goochland County. The bill defines a “qualified company” as a company engaged in manufacturing active pharmaceutical ingredients that, within the specified time window, is expected to make at least $2.148 billion in capital investment and create and maintain at least 468 new full-time jobs. In exchange, the company may receive grants from the Fund, with total grant payments capped at $130 million, and the grant proceeds may be used for construction and development of the facility or any other lawful purpose.
The measure establishes detailed eligibility terms, including what counts as capital investment, facility, and new full-time job, and requires a memorandum of understanding among the company, the Commonwealth, and the Virginia Economic Development Partnership Authority. The Fund is created as a special nonreverting state treasury fund, meaning unused balances remain available for future years rather than reverting to the general fund. The bill is structured as an economic development incentive tied to a large-scale life sciences manufacturing project and is limited by its definitions and geographic reference to Goochland County.
HB800 adds a new chapter to Title 59.1 of the Code of Virginia establishing a dedicated grant program for active pharmaceutical ingredient manufacturing. It authorizes state grant payments from a special nonreverting fund and sets statutory criteria for a single qualifying project, including investment, job creation, wage, and benefit requirements. The bill affects the Commonwealth’s economic development financing tools, the Virginia Economic Development Partnership Authority’s role in negotiating performance agreements, and the state treasury’s handling of appropriated grant funds.
The available record shows no committee transcripts or recorded votes, so there is no direct evidence of debate or opposition in the provided materials. Based on the bill’s enactment, the overall legislative outcome was favorable. The structure of the bill suggests support for attracting high-value manufacturing investment and jobs to Virginia, particularly in the pharmaceutical supply chain.
The main potential points of contention are the size of the public commitment, the project-specific nature of the incentive, and the use of state grant funds for a single company in one locality. Critics could question whether a grant cap of $130 million is justified by the expected economic return, whether the job and wage thresholds are sufficient safeguards, and whether directing benefits to one eligible locality and one qualified company is an appropriate use of statewide economic development resources. Supporters would likely emphasize the scale of the capital investment, the number of jobs, and the strategic value of domestic active pharmaceutical ingredient manufacturing.